(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 September 2014 (04.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/134355 A1

(51) International Patent Classification:
A61K 9/19 (2006.01) *A61K 31/69* (2006.01)
A61K 45/06 (2006.01) *A61P 35/00* (2006.01)
A61K 31/675 (2006.01) *A61P 37/02* (2006.01)

(21) International Application Number:
PCT/US2014/019137

(22) International Filing Date:
27 February 2014 (27.02.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/771,525 1 March 2013 (01.03.2013) US
61/887,165 4 October 2013 (04.10.2013) US

(71) Applicant: **ASTEX PHARMACEUTICALS, INC.** [US/US]; 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568 (US).

(72) Inventors: **AZAB, Mohammad**; 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568 (US). **TAVERNA, Pietro**; 4140 Dublin Boulevard, Suite 200, Dublin, CA 94568 (US). **COVRE, Alessia**; S.r.l. Sede Legale C/o Polo Technolgico PN, Via Roveredo 20/b, I-33170 Pordenone (IT). **CORAL, Sandra**; S.r.l. Sede Legale C/o Polo Technologico PN, Via Roveredo 20/b, I-33170 Pordenone (IT).

(74) Agents: **KENESY, Craig** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: DRUG COMBINATIONS




FIGURE 5

(57) Abstract: The invention provides combinations of derivatives of decitabine and other active agents, including T-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity. Methods of treating one or more myelodysplasia syndromes, cancers, haematological disorders, or diseases associated with abnormal haemoglobin synthesis using the combinations are described.

WO 2014/134355 A1